Symptomatic and functional outcomes after treatment with paliperidone palmitate 3-month formulation for 52 weeks in patients with clinically stable schizophrenia
Background: Paliperidone palmitate 3-monthly (PP3M) formulation is a long-acting, injectable antipsychotic treatment approved in many countries worldwide for the maintenance treatment of adult patients with schizophrenia. This single-arm, open-label, phase IIIb study evaluated the efficacy and safet...
Guardat en:
Autors principals: | , , , , , , , , |
---|---|
Format: | Llibre |
Publicat: |
SAGE Publishing,
2020-05-01T00:00:00Z.
|
Matèries: | |
Accés en línia: | Connect to this object online. |
Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|
Internet
Connect to this object online.3rd Floor Main Library
Signatura: |
A1234.567 |
---|---|
Còpia 1 | Disponible |